BTIG analyst Kambiz Yazdi initiated coverage of Zevra Therapeutics (ZVRA) with a Buy rating and $23 price target Zevra’s current valuation appears to reflect conservative adoption of Miplyffa limited to the existing U.S. diagnosed NPC population, establishing a downside floor based on that cohort, the analyst tells investors in a research note. Upside catalysts in 2026 include expansion of newly diagnosed U.S. patients, potential EU approval, patent term extension to lengthen exclusivity, and optionality from accelerating celiprolol development in VEDS, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing
- Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
- Zevra Therapeutics price target raised to $23 from $22 at Guggenheim
- Zevra Therapeutics: Strong NPC Enrollment Momentum and Undervalued Rare-Disease Pipeline Support Buy Rating and $26 Target
- Zevra Therapeutics Appoints Justin Renz as New CFO